The focus of the “2014 AHA/ACC Guideline for the Management of Patients With Valvular
Heart Disease” 9, 10 (2014 VHD guideline) was the diagnosis and management of adult …

The recommendations listed in this document are, whenever possible, evidence based. An
extensive review was conducted on literature published through March 1, 2020. Searches …

Valve thrombosis can occur in mechanical prosthetic valves and is increasingly recognised
in transcatheter and surgically implanted bioprosthetic valves. The risk of thrombosis of …

The “Guidelines on the Management of Valvular Heart Disease” were initially published as
the “Guidelines on Non-pharmacological Treatment of Valvular Heart Disease” in 2002 …

Background Prosthetic valve thrombosis (PVT) is one of the life-threatening complications of
prosthetic heart valve replacement. Due to the lack of randomized controlled trials, the …

Mechanical prosthetic heart valves, though more durable than bioprostheses, are more
thrombogenic and require lifelong anticoagulation. Mechanical valve dysfunction can be …

All foreign bodies inserted in the circulatory system are thrombogenic and require temporary
or lifelong antithrombotic therapies to prevent thrombosis. The adequate level of …

Prosthetic heart valve interventions continue to evolve with new innovations in surgical and
transcatheter technologies. We compared the recommendations from the 2017 American …

We describe successful usage of low dose Tissue plasminogen activator (tPA)(30–50 mg) in
three COVID19 critically ill patients, who were in worsening respiratory failure in-spite of …

Introduction: Prosthetic heart valve thrombosis is a life-threatening complication after valve
replacement surgery. Although subtherapeutic anticoagulation is the main cause, there are …